BMI View: The Greek pharmaceutical market will continue to be characterised by mandated pricereductions, state intervention in the trade of pharmaceutical goods, regressive revenue taxes, unpaid debtsand drug shortages. Moreover, the Greek government will continue to shift the burden of healthcarespending onto its citizens, requiring co-payments for expensive drugs and payments for outpatient visits.While we continue to hold to our view that Germany and the rest of the EU may reduce the focus onausterity and introduce some pro-growth strategies, these are unlikely to generate any upside for thepharmaceutical industry and structural reforms within Greece will be mainta...
No comments:
Post a Comment